The objective of this nested trial is to directly compare daptomycin to vancomycin as the backbone therapy for eligible MRSA-B.
MRSA infections result in higher crude mortality than MSSA infections. The current standard therapy in many centres for MRSA-B is vancomycin. Compared with β-lactams, vancomycin kills MSSA more slowly, has less penetration of infected tissue, and in observational studies is associated with poorer patient outcomes. Alternative agents to vancomycin have become available, including daptomycin. However, daptomycin has not been demonstrated to be superior to vancomycin for MRSA-B.
Hypothesis: Within the directly randomised comparison, daptomycin will have a superior probability of attaining a higher DOOR outcome at day 90 in adults.
Sample size: 300 participants
Lead Investigator: Prof. Todd C. Lee - McGill University, Montreal, Canada
SNAP Trial
SNAPstrat: Patient stratification using SAB sub-phenotypes
Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials
Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia
A statistical genomics framework to improve prediction of treatment outcomes of Staphylococcus aureus bacteraemia (SAB)
